Clinical Trials

Our Clinical Trials articles highlight top clinical trials, their results, and how patients can participate in them.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

Recent Articles

Discover MyeloMATCH: A New Approach to Accelerate AML and MDS Research

July 12, 2024

MDS specialist Harry Erba, MD, PhD, shared insight about a new treatment decision-making model for AML and MDS patients called myeloMATCH.

Luspatercept Can Improve Anemia and Reduce Transfusion Dependency in MDS

June 23, 2024

Luspatercept, also known as Reblozyl, is a medication used to treat MDS patients with anemia.

Study of Evorpacept and Azacitidine for High-Risk MDS

May 07, 2024

Discover Evorparcept's potential in high-risk MDS: ASPEN-02 study insights, safety, and treatment efficacy for patients seeking new options.

When Should I Consider A Clinical Trial For MDS?

April 22, 2024

Delve into the benefits of clinical trials, such as access to the latest therapies and medical advancements, and navigate your treatment options wisely.

ASH 2023: Venetoclax Combined With Azacitidine For High-Risk MDS

February 06, 2024

Early responses from the ven/aza combination treatment provided an effective avenue for patients to receive a stem cell transplant.

The Promising Treatment Of Imetelstat And Transfusion Independence

October 05, 2023

Imetelstat directly targets “malignant clones with abnormally high telomerase activity, enabling recovery of hematopoiesis (blood cell production).”

Promising ENHANCE Study For HR-MDS Pulled in Phase 3

July 28, 2023

Gilead announced they would be discontinuing their Phase 3 ENHANCE study, which was looking at Magrolimab in High-Risk MDS (HR-MDS) patients.

Clinical Trial - Selinexor (KPT-330) For MDS

March 24, 2023

Can Selinexor improve blood counts and bone marrow function in MDS patients?

The STIMULUS MDS-US Clinical Trial: Sabatolimab Added to HMA in Higher Risk MDS

February 08, 2023

Patients with intermediate-, high-, or very-high-risk myelodysplastic syndrome (MDS) need durable treatment options with favorable tolerability.

EHA Congress 2022: Magrolimab Plus Azacitidine for Untreated Higher-Risk MDS - Phase 1b Results

June 29, 2022

Dr. David Sallman speaks to us at the 2022 EHA meeting about his trial of magrolimab and azacitidine in high-risk MDS, a condition that can transform into AML.